Literature DB >> 19168405

Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma.

Y G Li1, N Zhang.   

Abstract

BACKGROUND/AIMS: To investigate the clinical significance of serum Tu M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma.
METHODS: The tumour markers (Tu M2-PK and CA19-9) in 115 patients with cholangiocarcinoma, 85 patients with benign disease and 120 blood donors were detected by ELISA.
RESULTS: The levels of serum Tu M2-PK and CA19-9 were markedly higher in the patients with cholangiocarcinoma than in controls (P<0.05). Tu M2-PK showed more sensitivity (84.2%) and specificity (90%) than CA19-9 (68.4%) and (75%).
CONCLUSIONS: Tu M2-PK may be used as a valuable diagnosis marker in cholangiocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19168405     DOI: 10.1016/j.dld.2008.11.010

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  13 in total

1.  Elevated serum level of carbohydrate antigen 19-9 in benign biliary stricture diseases can reduce its value as a tumor marker.

Authors:  Mao-Song Lin; Jun-Xing Huang; Hong Yu
Journal:  Int J Clin Exp Med       Date:  2014-03-15

2.  Comparative effectiveness of pyruvate kinase M2 in bile, serum carbohydrate antigen 19-9, and biliary brushings in diagnosing malignant biliary strictures.

Authors:  Udayakumar Navaneethan; Vennisvasanth Lourdusamy; Earl Poptic; Jeffrey P Hammel; Madhusudhan R Sanaka; Mansour A Parsi
Journal:  Dig Dis Sci       Date:  2014-10-25       Impact factor: 3.199

3.  Bilirubin levels predict malignancy in patients with obstructive jaundice.

Authors:  Giuseppe Garcea; Wee Ngu; Christopher P Neal; Ashley R Dennison; David P Berry
Journal:  HPB (Oxford)       Date:  2011-06       Impact factor: 3.647

4.  Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer.

Authors:  Dipok Kumar Dhar; Steven W M Olde Damink; James Hal Brindley; Andrew Godfrey; Michael H Chapman; Neomal S Sandanayake; Fausto Andreola; Sybille Mazurek; Tayyaba Hasan; Massimo Malago; Stephen P Pereira
Journal:  Cancer       Date:  2012-08-01       Impact factor: 6.860

5.  Biomarkers for the Diagnosis of Cholangiocarcinoma: A Systematic Review.

Authors:  Gyem Tshering; Palden Wangyel Dorji; Wanna Chaijaroenkul; Kesara Na-Bangchang
Journal:  Am J Trop Med Hyg       Date:  2018-04-05       Impact factor: 2.345

6.  Metabolites of purine nucleoside phosphorylase (NP) in serum have the potential to delineate pancreatic adenocarcinoma.

Authors:  Shaiju K Vareed; Vadiraja B Bhat; Christopher Thompson; Vihas T Vasu; Damian Fermin; Hyungwon Choi; Chad J Creighton; Sitaram Gayatri; Ling Lan; Nagireddy Putluri; Gagan Singh Thangjam; Punit Kaur; Mohsen Shabahang; Judith G Giri; Alexey I Nesvizhskii; Alexander A A Asea; Anil G Cashikar; Arundhati Rao; James McLoughlin; Arun Sreekumar
Journal:  PLoS One       Date:  2011-03-23       Impact factor: 3.240

7.  Diagnostic and prognostic serum marker of cholangiocarcinoma (Review).

Authors:  Xiaojun Zeng; Hualin Tao
Journal:  Oncol Lett       Date:  2014-11-10       Impact factor: 2.967

8.  The diagnostic value of brush cytology alone and in combination with tumor markers in pancreaticobiliary strictures.

Authors:  Ufuk Barış Kuzu; Bülent Ödemiş; Nesrin Turhan; Erkan Parlak; Selçuk Dişibeyaz; Nuretdin Suna; Erkin Öztaş; Muhammet Yener Akpınar; Adem Aksoy; Serkan Torun; Hakan Yıldız; Ertuğrul Kayaçetin
Journal:  Gastroenterol Res Pract       Date:  2015-03-26       Impact factor: 2.260

9.  Pyruvate Kinase M2 and Lactate Dehydrogenase A Are Overexpressed in Pancreatic Cancer and Correlate with Poor Outcome.

Authors:  Goran Hamid Mohammad; S W M Olde Damink; Massimo Malago; Dipok Kumar Dhar; Stephen P Pereira
Journal:  PLoS One       Date:  2016-03-18       Impact factor: 3.240

Review 10.  Novel endoscopic approaches in the diagnosis and management of biliary strictures.

Authors:  Margaret G Keane; Neale J Marlow; Stephen P Pereira
Journal:  F1000Prime Rep       Date:  2013-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.